VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | PEARL study: fremanezumab for chronic or episodic migraine in the real world

Messoud Ashina • 29 May 2020
EAN 2020
Headache Antibodies Fremanezumab
PEARL Prevention Treatment Trial Updates

Messoud Ashina, MD, PhD, DMSc, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, discusses the PEARL study protocol, a pan-European prospective observational study of fremanezumab effectiveness in patients with chronic or episodic migraine in the real world. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Messoud Ashina

4:14
BKCa channels: potential novel anti-migraine target
Messoud Ashina • 29 May 2020
3:29
The evolving migraine prevention landscape: EAN 2020 highlights
Messoud Ashina • 29 May 2020
1:47
Anti-CGRP monoclonal antibodies for difficult to treat migraines: DELIVER trial
Messoud Ashina • 23 Jun 2022
3:04
PACAP as a future target for anti-migraine medication
Messoud Ashina • 23 Jun 2022

Related Videos

2:58
Exploring the link between migraine and psychiatric comorbidities
Claudia Altamura • 2 Jul 2023
2:01
Targeting CGRP: Is it better to target the ligand or receptor in migraine prevention?
Claudia Altamura • 2 Jul 2023
0:53
Factors influencing genetic testing for hemiplegic migraine
Irene de Boer • 1 Jul 2023
1:18
The potential of combination therapy in migraine
Alan Rapoport • 1 Jul 2023
The content of VJNeurology is intended for healthcare professionals